Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.61 CAD 0.57% Market Closed
Market Cap: 261.7m CAD
Have any thoughts about
Profound Medical Corp?
Write Note

Profound Medical Corp
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Profound Medical Corp
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Other Current Liabilities
$676k
CAGR 3-Years
-21%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Other Current Liabilities
$24k
CAGR 3-Years
-90%
CAGR 5-Years
-76%
CAGR 10-Years
-46%
Opsens Inc
TSX:OPS
Other Current Liabilities
CA$2.3m
CAGR 3-Years
30%
CAGR 5-Years
13%
CAGR 10-Years
28%
Nanalysis Scientific Corp
XTSX:NSCI
Other Current Liabilities
CA$2.2m
CAGR 3-Years
-12%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedMira Inc
XTSX:MIR
Other Current Liabilities
CA$2.6m
CAGR 3-Years
-4%
CAGR 5-Years
71%
CAGR 10-Years
37%
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
259.8m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
5.8 CAD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Profound Medical Corp's Other Current Liabilities?
Other Current Liabilities
676k USD

Based on the financial report for Jun 30, 2024, Profound Medical Corp's Other Current Liabilities amounts to 676k USD.

What is Profound Medical Corp's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-9%

Over the last year, the Other Current Liabilities growth was -31%. The average annual Other Current Liabilities growth rates for Profound Medical Corp have been -21% over the past three years , -9% over the past five years .

Back to Top